Viewing nowEmpamax Tablet 10 mg (Empagliflozin L-Proline)
Empagliflozin L-Proline 12.55mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

MFDS item code 202107167 · Approved 2021.10.27 · Insurance code 643309700
Treatment of type 2 diabetes mellitus, chronic heart failure, and chronic kidney disease
This drug is used in conjunction with diet and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It is also used with other medications to reduce the risk of death and hospitalization from cardiovascular disease in patients with chronic heart failure. In adult patients with chronic kidney disease, it helps lower the risk of kidney function deterioration and cardiovascular death. Overall, this drug is effective in improving the health of patients with diabetes, heart failure, and kidney disease.
Type 2 diabetes mellitus The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. Chronic heart failure The recommended dose of this medicine is 10 mg once daily. Chronic kidney disease The recommended dose of this medicine is 10 mg once daily. This medicine should be administered in combination with other standard therapies for chronic kidney disease. Type 2 diabetes mellitus, chronic heart failure, and chronic kidney disease When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment Type 2 diabetes mellitus This medicine is not recommended to improve glycemic control in patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2. No dose adjustment is necessary in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. This medicine should not be used in patients with end-stage renal disease (ESRD) or those receiving dialysis, as efficacy is not expected. Chronic heart failure This medicine should not be used in patients with an estimated glomerular filtration rate (eGFR) below 20 ml/min/1.73m2. Chronic kidney disease This medicine may be used regardless of renal function. However, because experience is limited, initiation of treatment with this medicine is not recommended in patients with an estimated glomerular filtration rate (eGFR) below 20 ml/min/1.73m2. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered (see Precautions, 4. General Precautions).
This drug should not be used by patients who have an allergic reaction to the active ingredient, patients with type 1 diabetes, or those with diabetic ketoacidosis. Patients with decreased kidney function should use this drug cautiously and should have their kidney function tested before and regularly during use. It is especially not recommended for patients with very low kidney function or those on dialysis. When used in conjunction with insulin or medications that promote insulin secretion, the risk of hypoglycemia may increase; therefore, dosage adjustments of these medications may be necessary when used together with this drug. This drug may cause side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, and decreased fluid volume, so symptoms should be monitored closely. Ensure immediate medical consultation if symptoms like vomiting, abdominal pain, or difficulty breathing occur due to the risk of serious metabolic diseases known as ketoacidosis. Elderly patients and those at risk of fluid loss should be cautious about dehydration and hypotension, and it is important to regularly check blood pressure and fluid status. Cases of liver damage have been reported with this drug, so caution is needed in patients with liver function abnormalities. Additionally, this drug can cause serious urinary infections such as urosepsis or pyelonephritis, so immediate treatment is necessary if symptoms of urinary infections occur. It is recommended that pregnant women not use this drug, and breastfeeding should be discontinued during treatment with this drug. Pediatric and adolescent patients (under 18 years) should not use this drug as its safety and efficacy have not been established. Caution is necessary when driving or operating machinery due to the risk of hypoglycemia during treatment with this drug. No specific toxic symptoms have been reported in the event of overdose, but if overdose is suspected, immediate medical attention should be sought. Lastly, this drug should be kept out of the reach of children and not transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to avoid exposure to light or air. It is also recommended to store at room temperature between 1 to 30 degrees Celsius.
Light yellow, convex on both sides with rounded edges, film-coated tablet
30 tablets/box [10 tablets/ptp x 3], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.